Advertisement
Australia markets closed

  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     

  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     

  • AUD/USD

    0.6413
    -0.0012 (-0.19%)
     

  • OIL

    83.85
    +1.12 (+1.35%)
     

  • GOLD

    2,394.90
    -3.10 (-0.13%)
     

  • Bitcoin AUD

    98,804.05
    +3,773.15 (+3.97%)
     

  • CMC Crypto 200

    1,281.23
    -31.39 (-2.39%)
     

  • AUD/EUR

    0.6023
    -0.0008 (-0.13%)
     

  • AUD/NZD

    1.0892
    +0.0017 (+0.16%)
     

  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     

  • NASDAQ

    17,394.31
    -99.31 (-0.57%)
     

  • FTSE

    7,877.05
    +29.06 (+0.37%)
     

  • Dow Jones

    37,775.38
    +22.07 (+0.06%)
     

  • DAX

    17,837.40
    +67.38 (+0.38%)
     

  • Hang Seng

    16,195.49
    -190.38 (-1.16%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

Corcept Therapeutics Incorporated
·1-min read
Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated

MENLO PARK, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on August 3, 2022. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).

Conference Call Information
Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number, and a unique access PIN. Each access PIN will accommodate one caller.

Additionally, a listen-only webcast will be available by clicking here.

ADVERTISEMENT

A replay of the call will be available on the Investors / Events tab of www.corcept.com.

About Corcept Therapeutics

Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. The company is conducting clinical trials of its leading cortisol modulators as potential treatments for patients with Cushing’s syndrome, ovarian, adrenal and prostate cancer, weight gain caused by the use of antipsychotic medications and liver disease. Corcept’s drug Korlym® was the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome.

CONTACT:
Corcept Therapeutics
Investor Relations
ir@corcept.com
www.corcept.com